Recro to Report Financial Results for Fourth Quarter and Year-end 2021 on March 1, 2022
22 févr. 2022 16h05 HE
|
Recro Pharma, Inc.
SAN DIEGO and GAINESVILLE, Ga., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASDAQ: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving...
Recro Appoints Eduardo Uribe as Head of Quality for Recro San Diego
19 janv. 2022 07h00 HE
|
Recro Pharma, Inc.
SAN DIEGO and GAINESVILLE, Ga., Jan. 19, 2022 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex...
Recro Reports Inducement Grants For New Staff
06 janv. 2022 16h05 HE
|
Recro Pharma, Inc.
SAN DIEGO, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and...
Recro to Present at Stephens Annual Investment Conference
02 déc. 2021 07h00 HE
|
Recro Pharma, Inc.
SAN DIEGO and GAINESVILLE, Ga., Dec. 02, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASDAQ: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving...
Recro Reports Third Quarter 2021 Financial Results
09 nov. 2021 16h05 HE
|
Recro Pharma, Inc.
Acquisition of IriSys, Inc. Significantly Expands Customer Pipeline, Facilities and Capabilities Annual Revenue Guidance Increased to between $74 and $76 million Recorded Q3 2021 Revenues of...
Recro Enters Into Master Commercial Supply and Services Agreement With Otsuka
27 oct. 2021 07h00 HE
|
Recro Pharma, Inc.
Agreement Establishes Recro as Commercial Supplier for Otsuka Deal Validates Recro’s “Second Source” Strategy of Supporting Commercial Programs as U.S.-Based Supplier GAINESVILLE, Ga. and SAN...
Recro Awarded Development and Manufacturing Contract by National Institutes of Health (NIH) to Support Novel Nasal Spray Analgesic
20 oct. 2021 07h00 HE
|
Recro Pharma, Inc.
GAINESVILLE, Ga. and SAN DIEGO, Oct. 20, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex...
Recro Reports Inducement Grants For New Staff
06 oct. 2021 07h00 HE
|
Recro Pharma, Inc.
EXTON, Penn. and SAN DIEGO, Oct. 06, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex...
Recro Signs Renewable Energy Agreement With Georgia Power
21 sept. 2021 07h00 HE
|
Recro Pharma, Inc.
EXTON, Pa., Sept. 21, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and...
Recro and BioCorRx Expand Development and Manufacturing Relationship to Support BICX104, an Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder
08 sept. 2021 07h00 HE
|
Recro Pharma, Inc.; BioCorRx, Inc.
SAN DIEGO and ANAHEIM, Calif., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex...